嘉事堂(002462) - 2024 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2024 was ¥24,018,607,695.13, a decrease of 19.93% compared to ¥29,996,240,361.78 in 2023[15] - The net profit attributable to shareholders for 2024 was ¥160,668,362.95, down 35.75% from ¥250,060,041.68 in the previous year[15] - The net profit after deducting non-recurring gains and losses was ¥80,203,887.73, a decline of 66.51% from ¥239,475,788.49 in 2023[15] - The basic earnings per share for 2024 was ¥0.55, representing a decrease of 36.05% compared to ¥0.86 in 2023[15] - The total assets at the end of 2024 were ¥14,037,951,940.30, down 18.01% from ¥17,120,851,592.43 at the end of 2023[15] - The cash flow from operating activities for 2024 was ¥180,355,187.36, a significant decrease of 88.70% from ¥1,595,439,529.42 in 2023[15] - The company reported a significant gain from the disposal of non-current assets, totaling 201.43 million CNY in 2024, compared to 845.56 thousand CNY in 2023[22] - The company reported a net profit of ¥321,674,900, with a significant discrepancy between net profit and cash flow from operating activities[52] Revenue Breakdown - The pharmaceutical wholesale segment generated CNY 22,599,917,803, accounting for 94.09% of total revenue, with a year-on-year decline of 20.23%[40] - Revenue from pharmaceutical logistics increased by 15.79% to CNY 441,324,131.09, while revenue from pharmaceutical retail decreased by 23.94% to CNY 977,365,760.55[40] - The Beijing region contributed CNY 10,999,806,448, which is 45.80% of total revenue, showing a slight decline of 1.40% year-on-year[40] Market Position and Strategy - The company ranked 11th in the national pharmaceutical commercial industry in 2023, indicating a strong market position[26] - The company is focusing on expanding its logistics services to enhance customer stickiness and improve service capabilities[28] - The company is actively participating in the construction of a pension ecosystem, aligning with national strategies to enhance public health services[27] - The company is leveraging digitalization and intelligent governance to strengthen its competitive edge in the pharmaceutical distribution sector[26] - The company is committed to integrating its pharmaceutical and healthcare services with financial services to support business expansion[32] Governance and Management - The company has established an effective performance evaluation and incentive constraint mechanism, which is being gradually improved[91] - The company maintains a complete and independent business system, with no reliance on related transactions with the largest shareholder[95] - The company has a fully independent financial accounting system and management practices, ensuring independent financial decision-making[97] - The board of directors and supervisory board operate independently, ensuring that the interests of minority shareholders are protected[88][89] - The company is committed to maintaining a strong governance structure with independent directors overseeing its operations[115] Shareholder Engagement - The company held its first temporary shareholders' meeting on March 29, 2024, with an investor participation rate of 36.39%[99] - The annual shareholders' meeting for 2023 took place on May 21, 2024, with a participation rate of 36.41%[99] - The second temporary shareholders' meeting for 2024 was held on July 22, 2024, with a participation rate of 40.90%[99] - The third temporary shareholders' meeting for 2024 is scheduled for December 30, 2024, with a participation rate of 40.95%[99] Employee and Workforce - The total number of employees at the end of the reporting period is 1,969, with 1,764 from major subsidiaries and 192 from the parent company[135] - The educational background of employees includes 62 with postgraduate degrees, 744 with bachelor's degrees, 777 with associate degrees, and 386 with high school or lower education[136] - The average tenure of pharmaceutical professionals in the company exceeds 18 years, ensuring a highly specialized workforce[36] Risk Management and Compliance - The company has implemented a risk management approach that includes risk avoidance, reduction, sharing, and acceptance to effectively control risks[150] - The internal control system is designed to ensure compliance with laws and regulations, enhance management levels, and protect investor interests[146] - The company has established a comprehensive internal control system consisting of 13 categories, including financial management, risk management, and internal audit systems[153] Environmental and Social Responsibility - The company actively participated in poverty alleviation efforts, purchasing agricultural products worth approximately 640,000 yuan from targeted assistance counties[176] - The company has established a scientific and efficient environmental management process, adhering to various environmental laws and regulations[174] - The company provided drug delivery services to nearly 2,000 rural health clinics in remote areas, with a total of 2.6055 million deliveries valued at over 400 million yuan[177] Future Outlook and Investments - The company is investing in new technology development, allocating 100 million yuan for R&D in the upcoming year[126] - Market expansion plans include entering two new provinces, which are projected to increase market share by 5%[126] - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million yuan earmarked for potential deals[126] Dividend Policy - The company has a cash dividend policy that stipulates a minimum of 30% of the annual consolidated net profit for distribution[139] - The proposed cash dividend is 1.7 yuan per 10 shares, amounting to a total cash dividend of 49,590,210.40 yuan, based on a total share capital of 291,707,120 shares[140]